Maintenance Chemotherapy in Ovarian Cancer: A Trial-Sequential Analysis

Abstract

<p class="MsoNormal"> <span lang="EN-GB"><span style="font-family:Verdana;">In patients with epithelian ovarian cancer who have achieved remission after initial surgery and induction chemotherapy, the role of maintenance chemotherapy is controversial. We carried out a trial-sequential analysis that included 4 randomised controlled trials. The end-point was progression at 3 years while the boundary for non-inferiority was set at ±20% in risk ratio. The results of our trial-sequential analysis indicated the futility of maintenance chemotherapy, </span><i><span style="font-family:Verdana;">i.e.</span></i><span style="font-family:Verdana;"> proof of no effectiveness. Consequently, no further trials of this type should be performed to assess the effectiveness of this intervention in this clinical condition</span></span><span lang="EN-US" style="font-family:Verdana;">.</span><span lang="EN-US"><o:p></o:p></span> </p> <p class="MsoNormal"> <span lang="EN-US" style="font-family:Verdana;"> </span> </p

Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer

“…A total of 124 vaccine doses were administered. The mean number of Vigil doses administered was 5.9 (range of [1][2][3][4][5][6][7][8][9][10][11][12]. There was no difference in patient demographics including age between the overall population and those undergoing NanoString ® .…”

“…Additionally, the majority of advanced-stage ovarian cancer patients relapse within 2 years [ 2 ]. Research has involved developing improved maintenance regimens, which provide improvements in progression-free survival (PFS) [ 5 , 6 ]. In particular, poly (ADP-ribose) polymerase (PARP) inhibitors have shown benefit in prolonging PFS; however, this benefit is predominately in the BRCA1/2 mutant population, with limited efficacy in BRCA1/2 wild-type individuals [ 7 , 8 , 9 , 10 ].…”